uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Do steroids increase lymphoma risk? A case-control study of lymphoma risk in polymyalgia rheumatica/giant cell arteritis
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Rheumatology.
Show others and affiliations
2005 (English)In: Annals of the Rheumatic Diseases, ISSN 0003-4967, E-ISSN 1468-2060, Vol. 64, no 12, 1765-1768 p.Article in journal (Refereed) Published
Abstract [en]


Recent studies indicate increased risks of malignant lymphomas among individuals treated with corticosteroids, but have not taken into account the underlying reasons for steroid use, so the increased risks might be attributable to the underlying disease or concomitant treatments other than steroids. Polymyalgia rheumatica (PMR) and temporal arteritis (giant cell arteritis, GCA) are common inflammatory conditions treated with steroids as single immunosuppressive therapy, but data on lymphoma risk in GCA/PMR are limited.


To assess the risk of lymphoma associated with steroid treatment of GCA/PMR.


The association between GCA/PMR and malignant lymphomas (overall, and separately for non-Hodgkin lymphoma, Hodgkin lymphoma, and chronic lymphatic leukaemia) was examined in a nationwide, population based, case-control study of 42,676 lymphoma cases and 78,487 matched population controls, using prospectively recorded data on lymphomas from the Swedish cancer register 1964-2000 and data on pre-lymphoma hospital admissions for GCA/PMR from the Swedish inpatient register 1964-2000. Odds ratios (OR) associated with a pre-lymphoma hospital admission for GCA/PMR were calculated using conditional logistic regression.


153 lymphoma cases and 345 population controls had a history of GCA/PMR, resulting in an overall OR for malignant lymphomas of 0.81 (95% confidence interval, 0.67 to 0.98). The OR varied little with lymphoma type, sex, age, and calendar period. The OR for GCA was 0.67 (0.48 to 0.98) and for PMR, 0.83 (0.67 to 1.04).


Treated GCA is not associated with increased lymphoma risks, which suggests that even at considerable cumulative doses, steroids may not appreciably increase lymphoma risk.

Place, publisher, year, edition, pages
2005. Vol. 64, no 12, 1765-1768 p.
Keyword [en]
Aged, Antirheumatic Agents/*adverse effects/therapeutic use, Epidemiologic Methods, Female, Glucocorticoids/*adverse effects/therapeutic use, Hodgkin Disease/chemically induced/epidemiology, Humans, Leukemia; Lymphocytic; Chronic/chemically induced/epidemiology, Lymphoma/*chemically induced/epidemiology, Lymphoma; Non-Hodgkin/chemically induced/epidemiology, Male, Middle Aged, Polymyalgia Rheumatica/*drug therapy, Research Support; Non-U.S. Gov't, Sweden/epidemiology, Temporal Arteritis/*drug therapy
National Category
Rheumatology and Autoimmunity
URN: urn:nbn:se:uu:diva-76844DOI: 10.1136/ard.2005.036459PubMedID: 15843445OAI: oai:DiVA.org:uu-76844DiVA: diva2:104756
Available from: 2006-06-27 Created: 2006-06-27 Last updated: 2014-09-30Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Baecklund, Eva
By organisation
In the same journal
Annals of the Rheumatic Diseases
Rheumatology and Autoimmunity

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 227 hits
ReferencesLink to record
Permanent link

Direct link